Q2 EPS Estimates for Rockwell Medical Cut by HC Wainwright

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities researchers at HC Wainwright lowered their Q2 2025 earnings per share estimates for Rockwell Medical in a research report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.01) per share for the quarter, down from their prior estimate of $0.02. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at $0.01 EPS.

RMTI has been the subject of several other reports. StockNews.com lowered shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Rodman & Renshaw initiated coverage on shares of Rockwell Medical in a research note on Thursday, November 14th. They set a “buy” rating and a $5.00 price target on the stock. Finally, RODMAN&RENSHAW upgraded Rockwell Medical to a “strong-buy” rating in a research note on Thursday, November 14th.

Rockwell Medical Trading Down 2.6 %

Rockwell Medical stock opened at $2.25 on Tuesday. Rockwell Medical has a 52-week low of $1.16 and a 52-week high of $5.15. The company has a market cap of $72.72 million, a P/E ratio of -45.00 and a beta of 1.50. The company has a quick ratio of 2.00, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The business has a 50-day simple moving average of $3.46 and a two-hundred day simple moving average of $2.66.

Hedge Funds Weigh In On Rockwell Medical

A number of hedge funds have recently modified their holdings of RMTI. Vanguard Group Inc. boosted its stake in shares of Rockwell Medical by 4.0% in the first quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock worth $1,856,000 after acquiring an additional 43,302 shares during the period. Armistice Capital LLC lifted its holdings in Rockwell Medical by 22.5% in the 2nd quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after purchasing an additional 592,000 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Rockwell Medical by 877.1% in the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock worth $181,000 after purchasing an additional 92,189 shares during the period. Beacon Financial Advisory LLC purchased a new stake in Rockwell Medical during the 3rd quarter valued at approximately $98,000. Finally, Verus Capital Partners LLC purchased a new stake in Rockwell Medical during the 3rd quarter valued at approximately $51,000. 23.31% of the stock is currently owned by institutional investors.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.